You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
|
|---|---|
| Published in |
Translational Neurodegeneration, September 2013
|
| DOI | 10.1186/2047-9158-2-19 |
| Pubmed ID | |
| Authors |
Kay Cheong Teo, Shu-Leong Ho |
| Abstract |
There is a substantial amount of evidence from experimental parkinsonian models to show the neuroprotective effects of monoamine oxidase-B (MAOB) inhibitors. They have been studied for their potential disease-modifying effects in Parkinson's disease (PD) for over 20 years in various clinical trials. This review provides a summary of the clinical trials and discusses the implications of their results in the context of disease-modification in PD. Earlier clinical trials on selegiline were confounded by symptomatic effects of this drug. Later clinical trials on rasagiline using delayed-start design provide newer insights in disease-modification in PD but success in achieving the aims of this strategy remain elusive due to obstacles, some of which may be insurmountable. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | <1% |
| Unknown | 116 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 28 | 24% |
| Student > Master | 18 | 15% |
| Student > Ph. D. Student | 16 | 14% |
| Researcher | 13 | 11% |
| Student > Postgraduate | 7 | 6% |
| Other | 13 | 11% |
| Unknown | 22 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 17 | 15% |
| Biochemistry, Genetics and Molecular Biology | 16 | 14% |
| Medicine and Dentistry | 16 | 14% |
| Chemistry | 12 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 9% |
| Other | 19 | 16% |
| Unknown | 26 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2016.
All research outputs
#14,599,900
of 25,373,627 outputs
Outputs from Translational Neurodegeneration
#304
of 384 outputs
Outputs of similar age
#109,165
of 210,059 outputs
Outputs of similar age from Translational Neurodegeneration
#3
of 3 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 384 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 29.7. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,059 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.